Pfizer’s Maraviroc Deemed “Approvable” By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer says it is working with FDA to finalize product labeling for the HIV treatment as soon as possible.
You may also be interested in...
Pfizer’s Selzentry Wins FDA Approval For HIV
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.
Pfizer’s Selzentry Wins FDA Approval For HIV
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.
Takeda Outlicenses Two CCR5 Antagonists To Newly Formed Tobira
A new chemokine receptor 5 antagonist candidate licensed this week to Tobira Therapeutics by Takeda could provide a dosing advantage over other CCR5 antagonists in development, such as Pfizer's maraviroc and Schering-Plough's vicriviroc, according to Tobira CEO James Sapirstein